2. Signaling Pathways
  3. Immunology/Inflammation
  4. Complement System
  5. Complement System Agonist

Complement System Agonist

Complement System Agonists (10):

Cat. No. Product Name Effect Purity
  • HY-15701
    Leukadherin-1
    		Agonist ≥98.0%
    Leukadherin-1, a specific agonist of the leukocyte surface integrin CD11b/CD18, increases CD11b/CD18-dependent cell adhesion to fibrinogen with an EC50 of 4 μM. Leukadherin-1 enhances leukocyte adhesion to ligands (such as ICAM-1) and vascular endothelium and thus reduces leukocyte transendothelial migration and influx to the injury sites. Leukadherin-1 suppresses innate inflammatory signaling.
  • HY-P1345A
    TLQP-21 TFA
    		Agonist 99.90%
    TLQP-21 TFA, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent G-protein-coupled receptor complement-3a receptor1 (C3aR1) agonist (EC50: mouse TLQP-21=10.3 μM; human TLQP-21=68.8μM). TLQP-21 TFA activates C3aR1 to induce an increase of intracellular Ca2+. TLQP-21 TFA is used for the research in regulation of nociception and other relevant physiologic functions.
  • HY-128132
    C3a receptor agonist 1
    		Agonist 98.04%
    C3a receptor agonist 1 (compound benzeneacetamide) is a potent C3a receptor agonist. C3a receptor agonist 1 has the potential for the research of acute inflammation.
  • HY-15701B
    ADH-503
    		Agonist 98.04%
    ADH-503 ((Z)-Leukadherin-1 choline) is an orally active and allosteric CD11b agonist. ADH-503 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhances dendritic cell responses.
  • HY-15701A
    (Z)-Leukadherin-1
    		Agonist ≥98.0%
    (Z)-Leukadherin-1 (ADH-503 free base) is an orally active and allosteric CD11b agonist. (Z)-Leukadherin-1 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhances dendritic cell responses.
  • HY-P5506
    C5a Receptor agonist, W5Cha
    		Agonist 99.50%
    C5a Receptor agonist, W5Cha (Peptide 1) is a selective complement C5a receptor (C5aR) agonist (EC50=0.2 μM), a hexapeptide derived from the C-terminus of C5a with specific amino acid modifications. C5a Receptor agonist, W5Cha is able to interact with the Arg-206 site of the C5a receptor through its C-terminal arginine, thereby activating the receptor.
  • HY-P10639
    C5aR2 agonist P32
    		Agonist 99.82%
    C5aR2 agonist P32 (Ac-RHYPYWR-OH) is a C5aR2-selective agonist. C5aR2 agonist P32 has been shown to elicit multiple immunomodulatory activities, both by down-regulating the C5aR1-mediated cell signalling, and acting in a C5aR1-independent fashion, in vitro and in vivo.
  • HY-P1640
    (Trp63,Trp64)​-​C3a(63-77)
    		Agonist
    (Trp63,Trp64)​-​C3a(63-77) is a C3a synthetic analogue peptide, which exhibits Ca2+ stimulating efficacy in human neutrophils and hC3aR or mC3aR expressing RBL-2H3 cells with EC50 of 9.5, 2.0 and 0.8 nM, respectively.
  • HY-P1345
    TLQP-21
    		Agonist
    TLQP-21, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent G-protein-coupled receptor complement-3a receptor 1 (C3aR1) agonist (EC50: mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM). TLQP-21 activates C3aR1 to induce an increase of intracellular Ca2+. TLQP-21 is used for the research in regulation of nociception and other relevant physiologic functions.
  • HY-P10639A
    C5aR2 agonist P32 acetate
    		Agonist
    C5aR2 agonist P32 (Ac-RHYPYWR-OH) acetate is a C5aR2-selective agonist. C5aR2 agonist P32 acetate has been shown to elicit multiple immunomodulatory activities, both by down-regulating the C5aR1-mediated cell signalling, and acting in a C5aR1-independent fashion, in vitro and in vivo.